Investigating the effect of piroxicam injection in renal colic

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230808059084N1

Enrollment

176

Registered

2023-08-20

Start date

2023-07-23

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with renal colic.

Interventions

Intervention 1: Patients receiving piroxicam ampoule 40 mg/ml, one dose, once and intramuscularly from Caspian Tamim Company. Intervention 2: Control group:Patients receiving ketorolac 30 mg/ml in a s

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Desire and cooperation to participate in the study Suffering from renal colic for more than 6 months from the diagnosis of the disease by the doctor

Exclusion criteria

Exclusion criteria: Reluctance to participate in the study Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
Pain score on Visual Analogue Scale. Timepoint: Immediately, 15 and 30 minutes after injection. Method of measurement: Visual Analogue Scale.	—

Secondary

Measure	Time frame
Vital Signs. Timepoint: Immediately, 15 and 30 minutes after injection. Method of measurement: Visual Analogue Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehsa Bagdeli

Ahvaz University of Medical Sciences

mahsa.bagdli99@gmail.com+98 930 729 5540

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026